KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Receivables: 2013-2025

Historic Change in Receivables for Acadia Pharmaceuticals (ACAD) over the last 13 years, with Sep 2025 value amounting to $8.9 million.

  • Acadia Pharmaceuticals' Change in Receivables rose 235.61% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 15.57%. This contributed to the annual value of $1.9 million for FY2024, which is 94.81% down from last year.
  • Acadia Pharmaceuticals' Change in Receivables amounted to $8.9 million in Q3 2025, which was up 402.84% from $1.8 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Change in Receivables high stood at $15.9 million for Q2 2023, and its period low was -$12.2 million during Q3 2022.
  • For the 3-year period, Acadia Pharmaceuticals' Change in Receivables averaged around $5.1 million, with its median value being $5.5 million (2023).
  • Its Change in Receivables has fluctuated over the past 5 years, first slumped by 354.30% in 2021, then surged by 325.05% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Change in Receivables (Quarterly) stood at $3.7 million in 2021, then surged by 76.08% to $6.5 million in 2022, then declined by 15.43% to $5.5 million in 2023, then plummeted by 213.41% to -$6.2 million in 2024, then skyrocketed by 235.61% to $8.9 million in 2025.
  • Its Change in Receivables was $8.9 million in Q3 2025, compared to $1.8 million in Q2 2025 and $7.0 million in Q1 2025.